Literature DB >> 16048972

Preincubation of pneumococci with beta-lactams alone or combined with levofloxacin prevents quinolone-induced resistance without increasing intracellular levels of levofloxacin.

Philippe Cottagnoud1, Maggie Johnson, Marianne Cottagnoud, Laura Piddock.   

Abstract

Preincubation of pneumococci with sub-MIC concentrations of ceftriaxone (1/16x MIC), cefotaxime (1/8x MIC), and meropenem (1/4x MIC) alone or combined with levofloxacin (1/8x MIC) over 6 h prevents the emergence of levofloxacin-resistant mutants after 96 h of incubation but does not affect the intracellular accumulation of levofloxacin in two penicillin-resistant pneumococcal strains, suggesting a link between the mechanism of action of beta-lactams and the emergence of quinolone-induced resistance in pneumococci.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048972      PMCID: PMC1196276          DOI: 10.1128/AAC.49.8.3517-3519.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Ross Davidson; Rodrigo Cavalcanti; James L Brunton; Darrin J Bast; Joyce C S de Azavedo; Pamela Kibsey; Christine Fleming; Donald E Low
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  A study of the genetic material determining an enzyme in Pneumococcus.

Authors:  S LACKS; R D HOTCHKISS
Journal:  Biochim Biophys Acta       Date:  1960-04-22

3.  Gentamicin increases the efficacy of vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

Authors:  Philippe Cottagnoud; Cynthia M Gerber; Marianne Cottagnoud; Martin G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.

Authors:  Laura J V Piddock; M M Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.

Authors:  T D Gootz; R Zaniewski; S Haskell; B Schmieder; J Tankovic; D Girard; P Courvalin; R J Polzer
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.

Authors:  Stephanie J Schrag; Lesley McGee; Cynthia G Whitney; Bernard Beall; Allen S Craig; Miriam E Choate; James H Jorgensen; Richard R Facklam; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci.

Authors:  L Flatz; M Cottagnoud; F Kühn; J Entenza; A Stucki; P Cottagnoud
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

8.  Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.

Authors:  Steven D Brown; David J Farrell
Journal:  J Antimicrob Chemother       Date:  2004-08       Impact factor: 5.790

9.  Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro.

Authors:  F Kühn; M Cottagnoud; F Acosta; L Flatz; J Entenza; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Vancomycin acts synergistically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin.

Authors:  P Cottagnoud; M Cottagnoud; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more
  1 in total

Review 1.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.